Short Interest in Mainz Biomed NV (NASDAQ:QUCY) Decreases By 85.5%

Mainz Biomed NV (NASDAQ:QUCY) saw a significant drop in short interest during the month of May. As of May 29th, there was short interest totaling 1,522,115 shares, a drop of 85.5% from the May 14th total of 10,530,990 shares. Currently, 10.7% of the shares of the company are short sold. Based on an average daily volume of 15,034,560 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. Maxim Group downgraded Mainz Biomed from a “strong-buy” rating to a “hold” rating in a report on Friday, March 6th. Wall Street Zen raised Mainz Biomed to a “hold” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings upgraded Mainz Biomed from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Mainz Biomed Stock Performance

Mainz Biomed stock traded down $0.02 during midday trading on Thursday, hitting $1.90. 16,284,634 shares of the company’s stock were exchanged, compared to its average volume of 10,394,991. Mainz Biomed has a 12-month low of $0.30 and a 12-month high of $4.93. The stock has a market cap of $27.85 million, a PE ratio of -0.04 and a beta of 2.22. The business has a 50 day moving average price of $1.43.

Mainz Biomed (NASDAQ:QUCY) last issued its quarterly earnings data on Tuesday, March 31st. The company reported ($0.02) earnings per share (EPS) for the quarter. The business had revenue of $0.13 million for the quarter.

About Mainz Biomed

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.